- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Adaptimmune Therapeutics Plc (ADAP)"Adaptimmune Therapeutics Plc stock price live, this page displays NASDAQ ADAP stock exchange data. View the ADAP premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Adaptimmune Therapeutics Plc real time stock price chart below.
What Is the Adaptimmune Therapeutics Plc Stock Price Today?
The Adaptimmune Therapeutics Plc stock price today is 0.721.
What Is the Stock Symbol for Adaptimmune Therapeutics Plc?
The stock symbol for Adaptimmune Therapeutics Plc is ""ADAP.""
What Stock Exchange Does Adaptimmune Therapeutics Plc Trade On?
Adaptimmune Therapeutics Plc is listed and trades on the NASDAQ stock exchange.
Is Adaptimmune Therapeutics Plc a Good Stock to Buy?
Determining whether Adaptimmune Therapeutics Plc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ADAP quote. (ISIN: US00653A1079)"
What Is the Adaptimmune Therapeutics Plc Stock Price Today?
The Adaptimmune Therapeutics Plc stock price today is 0.721.
What Is the Stock Symbol for Adaptimmune Therapeutics Plc?
The stock symbol for Adaptimmune Therapeutics Plc is ""ADAP.""
What Stock Exchange Does Adaptimmune Therapeutics Plc Trade On?
Adaptimmune Therapeutics Plc is listed and trades on the NASDAQ stock exchange.
Is Adaptimmune Therapeutics Plc a Good Stock to Buy?
Determining whether Adaptimmune Therapeutics Plc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ADAP quote. (ISIN: US00653A1079)"
0.721
-0.004(0.00%)
Closed
Pre Market
0.732+0.011(+1.53%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.715
0.739
52 wk Range
0.430
2.050
ADAP Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.7150.739
52 wk Range
0.4302.050
Key Statistics
Edit
Book Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockADAP Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Neutral
Price Target
2.267
Upside
+214.424%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Adaptimmune Therapeutics Plc Company Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Adaptimmune Therapeutics Plc SWOT Analysis
FDA Milestone | Explore Adaptimmune's breakthrough with Tecelra's early FDA approval for synovial sarcoma, marking its entry into the commercial oncology market |
Financial Challenges | Delve into Adaptimmune's financial outlook, with projected negative EPS and a revised cash runway extending into late 2025 |
Pipeline Potential | Uncover the promise of Lete-cel, Adaptimmune's next major pipeline candidate, and its potential impact on the company's market position |
Market Dynamics | Analyze Adaptimmune's $727,000 list price for Tecelra and its implications for market adoption, revenue growth, and competitive positioning |
ADAP Full Pro Research
Institutional-Grade Stock Analysis
Understand how ADAP earns money
Financial health at a glance
Bearish and bullish outlooks
Latest expert insights
Actionable Pro Tips, and many more...
Gain access to 1400+ in-depth research reports on the most popular US stocks
Adaptimmune Therapeutics Plc Earnings Call Summary for Q3/2024
- Adaptimmune launched Tecelra, first engineered cell therapy for synovial sarcoma; strong financials with $215M liquidity
- Plans to activate 6-10 treatment centers for Tecelra; pipeline includes lete-cel and uza-cel for solid tumors
- SURPASS-3 trial for lete-cel progressing; full enrollment expected next year; Medicare coverage in place
- Anticipates consistent run rate operating expenses; collaborating with Galapagos for head and neck cancer trial
- Limited visibility on Tecelra patient eligibility; MRCLS not included on Tecelra label due to limited trial data
Last Updated: 2024/08/13, 00:38
Read Full TranscriptCompare ADAP to Peers and Sector
Metrics to compare | ADAP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipADAPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.1x | −3.3x | −0.7x | |
PEG Ratio | −0.06 | 0.00 | 0.00 | |
Price/Book | 2.3x | 1.9x | 2.6x | |
Price / LTM Sales | 1.1x | 5.5x | 3.2x | |
Upside (Analyst Target) | 177.4% | 90.0% | 44.5% | |
Fair Value Upside | Unlock | 13.5% | 6.6% | Unlock |
Analysts' Recommendations
6 Buy
2 Hold
1 Sell
Ratings:
9 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 2.267
(+214.38% Upside)
FAQ
What Is the Adaptimmune Therapeutics (ADAP) Stock Price Today?
The Adaptimmune Therapeutics stock price today is 0.721
What Stock Exchange Does Adaptimmune Therapeutics Trade On?
Adaptimmune Therapeutics is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Adaptimmune Therapeutics?
The stock symbol for Adaptimmune Therapeutics is "ADAP."
What Is the Adaptimmune Therapeutics Market Cap?
As of today, Adaptimmune Therapeutics market cap is 184.42M.
What is Adaptimmune Therapeutics Earnings Per Share?
The Adaptimmune Therapeutics EPS is -0.182.
What Is the Next Adaptimmune Therapeutics Earnings Date?
Adaptimmune Therapeutics will release its next earnings report on 26 Feb 2025.
From a Technical Analysis Perspective, Is ADAP a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.